Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | F2 | P00734 | 1/20 | 0.57 |
| ▸ | DAO | P14920 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 7/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | HPGD | P15428 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | CASP7 | P55210 | 1/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.53 |
| ▸ | RELA | Q04206 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12216734 | 0.84 | KDM4E (0.62) | KDM4EMAPTRAB9AKMT2ALMNA | |
| SCHEMBL4211785 | 0.79 | KDM4E (0.53) | KDM4EMAPTF2MAPK1RAB9A | |
| SCHEMBL166992 | 0.79 | F2 (0.63) | KDM4EMAPTF2DAOMAPK1 | |
| SCHEMBL13754450 | 0.79 | SMN1; SMN2 (0.59) | KDM4EMAPTF2DAOMAPK1 | |
| SCHEMBL27572930 | 0.79 | F2 (0.52) | KDM4EMAPTF2DAOMAPK1 | |
| SCHEMBL14627824 | 0.79 | MAPK1 (0.64) | KDM4EF2DAOMAPK1RAB9A | |
| SCHEMBL3241403 | 0.79 | AR (0.52) | KDM4EMAPTF2DAOMAPK1 | |
| SCHEMBL265403 | 0.78 | HPGD (0.49) | KDM4EMAPTF2DAOMAPK1 | |
| SCHEMBL6395252 | 0.77 | KDM4E (0.55) | KDM4EMAPTRAB9AKMT2ALMNA | |
| SCHEMBL7967944 | 0.77 | KMT2A (0.59) | KDM4EMAPTDAORAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295136-A1 | Analogs of Nitrofuran Antibiotics to Combat Resistance | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2023-09-21 | — | — | US | disclosed |
| EP-3309158-B1 | CRYSTALLINE FORM K OF RIVAROXABAN AND PROCESS FOR ITS PREPARATION | KRKA TOVARNA ZDRAVIL D D (SI) | 2022-03-16 | — | — | EP | disclosed |
| EP-3309158-B1 | CRYSTALLINE FORM K OF RIVAROXABAN AND PROCESS FOR ITS PREPARATION | KRKA TOVARNA ZDRAVIL D D (SI) | 2022-03-16 | — | — | EP | disclosed |
| US-20220009914-A1 | Analogs of Nitrofuran Antibiotics to Combat Resistance | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-13 | — | — | US | disclosed |
| WO-2019003141-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-03 | — | — | WO | disclosed |
| EP-2968995-B1 | INHIBITORS OF LRRK2 KINASE ACTIVITY | ELAN PHARMACEUTICALS LLC (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-3309158-A1 | CRYSTALLINE FORM K OF RIVAROXABAN AND PROCESS FOR ITS PREPARATION | Farma GRS, d.o.o. (SI) | 2018-04-18 | — | — | EP | disclosed |
| EP-3309158-A1 | CRYSTALLINE FORM K OF RIVAROXABAN AND PROCESS FOR ITS PREPARATION | Farma GRS, d.o.o. (SI) | 2018-04-18 | — | — | EP | disclosed |
| US-9828350-B2 | 5,6-dihydro-2H-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-28 | — | — | US | disclosed |
| EP-2935255-B1 | A PROCESS FOR PREPARATION OF RIVAROXABAN | FARMA GRS D O O (SI) | 2017-08-16 | — | — | EP | disclosed |
| WO-2014096214-A1 | A PROCESS FOR PREPARATION OF RIVAROXABAN | FARMA GRS, D.O.O. (SI) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014096214-A1 | A PROCESS FOR PREPARATION OF RIVAROXABAN | FARMA GRS, D.O.O. (SI) | 2014-06-26 | — | — | WO | disclosed |
| WO-2013120465-A1 | A PROCESS FOR THE PREPARATION OF RIVAROXABAN BASED ON THE USE OF (S)-EPICHLOROHYDRIN | ZENTIVA, K.S. (CZ) | 2013-08-22 | — | — | WO | disclosed |
| US-20130137730-A1 | INHIBITOR OF CASEIN KINASE 1DELTA AND CASEIN KINASE 1E | NB HEALTH LABORATORY CO., LTD. (JP) | 2013-05-30 | — | — | US | disclosed |
| US-20130109683-A1 | 5,6-DIHYDRO-2H-[1,4]OXAZIN-3-YL-AMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130109683-A1 | 5,6-DIHYDRO-2H-[1,4]OXAZIN-3-YL-AMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (US) | 2013-05-02 | — | — | US | disclosed |
| EP-2132193-B1 | SUBSTITUTED PYRROLIDINE AMIDES, THE PRODUCTION THEREOF, AND THE USE THEREOF AS MEDICATIONS | BOEHRINGER INGELHEIM INT (DE) | 2012-10-24 | — | — | EP | disclosed |
| WO-2007042146-A1 | MICROANGIOPATHY TREATMENT AND PREVENTION | BAYER HEALTHCARE AG (DE) | 2007-04-19 | — | — | WO | disclosed |
| WO-2005032468-A2 | MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-14 | — | — | WO | disclosed |
| WO-2004082687-A1 | LACTAM-CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295136-A1 | Analogs of Nitrofuran Antibiotics to Combat Resistance | ATF4, ATF1, FBL | KDM4E 2340/4885MAPT 4442/4885F2 4738/4885 |
| US-20130109683-A1 | 5,6-DIHYDRO-2H-[1,4]OXAZIN-3-YL-AMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | BACE2, BACE1, PSEN2 | KDM4E 3667/4885MAPT 34/4885F2 4033/4885 |
| US-20130137730-A1 | INHIBITOR OF CASEIN KINASE 1DELTA AND CASEIN KINASE 1E | CSNK1A1, CSNK1G1, CSNK1A1L | KDM4E 795/4885MAPT 966/4885F2 4229/4885 |
| US-20220009914-A1 | Analogs of Nitrofuran Antibiotics to Combat Resistance | ATF4, ATF1, FBL | KDM4E 2340/4885MAPT 4442/4885F2 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.